| Bioactivity | COX-2-IN-10 is a potent COX-2 inhibitor. COX-2-IN-10 inhibits the production of PGE2 in concentration dependent manner (IC50=2.54 µM). COX-2-IN-10 inhibits the expression of iNOS and COX-2 on mRNA and protein level . COX-2-IN-10 inhibits the production of IL-6, TNF-α and IL-1β[1]. |
| Invitro | COX-2-IN-10 (compound 9k) (10 µM, 24 h) exhibits high safety and did not show any significant cytotoxicity over LPS-Induced RAW264.7 macrophage cells[1].COX-2-IN-10 (0.4, 2, 10 µM) inhibits the production of PGE2 in concentration dependent manner in RAW264.7 macrophage cells (IC50=2.54 µM)[1].COX-2-IN-10 (2.5, 5, 10 μM) significantly inhibits the mRNA expression of iNOS and COX-2 at 10 μM[1].COX-2-IN-10 (2.5, 5, 10 μM) significantly inhibits iNOS and COX-2 protein level starting from 10 μM concentration[1].COX-2-IN-10 (2.5, 5, 10 μM; 1 h) inhibits the production of IL-6, TNF-α and IL-1β[1]. Cell Viability Assay[1] Cell Line: |
| Name | COX-2-IN-10 |
| Formula | C31H32FN5O2S |
| Molar Mass | 557.68 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Karim I. M, et al. Design, synthesis, in vitro determination and molecular docking studies of 4-(1-(tert-butyl)-3-phenyl-1H-pyrazol-4-yl) pyridine derivatives with terminal sulfonamide derivatives in LPS-induced RAW264.7 macrophage cells. Medicinal Chemis |